<DOC>
	<DOCNO>NCT00705874</DOCNO>
	<brief_summary>This study aim determine maximum tolerate dose CGC-11047 use individual combination gemcitabine , docetaxel , bevacizumab , erlotinib cisplatin 5-flurouracil sunitinib one 7 treatment arm . The dose CGC-11047 escalate maximum tolerated dose establish .</brief_summary>
	<brief_title>Study CGC-11047 When Used Individual Combinations With 1 ) Gemcitabine 2 ) Docetaxel 3 ) Bevacizumab 4 ) Erlotinib 5 ) Cisplatin 6 ) 5-Flurouracil 7 ) Sunitinib Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>This study use dose escalation design determine MTD CGC-11047 use individual combination gemcitabine , docetaxel , bevacizumab , erlotinib cisplatin 5-flurouracil sunitinib one 7 treatment arm . The dose CGC-11047 escalate cohort 3 patient dose escalation proceed treatment group independent dose escalation treatment group . CGC-11047 administer IV 60 minute dos gemcitabine , docetaxel , bevacizumab , cisplatin , 5-flurouracil sunitinib remain fixed accord respective product labeling .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>nonhematological advance solid tumor malignancy lymphoma curative therapy exist monotherapy gemcitabine docetaxel bevacizumab erlotinib cisplatin , 5flurouracil sunitinib would otherwise warrant . measurable disease base radiographic evaluation elevate tumor marker . ECOG 0 1 ( KPS &gt; 70 ) . Life expectancy &gt; 3 month . chemotherapy within 21 day radiotherapy within 4 week prior enter study know active brain metastasis leptomeningeal carcinomatosis . history myocardial infarction within prior 6 month , hospitalization congestive heart failure within prior 6 month , active treatment uncontrolled cardiac arrhythmia clinically significant gastrointestinal tract hemorrhage , require transfusion therapy , within prior 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>CGC-11047</keyword>
</DOC>